Polaryx Therapeutics

Polaryx Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for lysosomal storage disorders (LSDs) and other rare, life-threatening diseases. The company's primary focus is on repurposing and optimizing existing compounds to address the unmet medical needs of patients with genetic disorders that affect the central nervous system and other vital organs. Polaryx's lead product candidate, PLX-101, is an oral small molecule being developed for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as CLN2 disease. PLX-101 works by activating the Peroxisome Proliferator-Activated Receptor alpha (PPARα) and the Transcription Factor EB (TFEB), which are critical regulators of lysosomal biogenesis and autophagy. By enhancing these pathways, the therapy aims to reduce the accumulation of toxic storage material in cells, potentially slowing or halting disease progression. In addition to CLN2, the company is exploring the application of its technology platform across other forms of Neuronal Ceroid Lipofuscinosis (NCL) and various lysosomal storage diseases. Polaryx leverages a strategy of utilizing well-characterized molecules to accelerate clinical development timelines and reduce safety risks. The company is led by a management team with extensive experience in drug development and rare disease research, aiming to provide accessible, non-invasive treatment options for pediatric and adult patients worldwide.